Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma has received a demand notice dated 12th May, 2026 from the National Pharmaceutical Pricing Authority (NPPA) directing the company to deposit ₹4,92,25,923 (approximately ₹4.92 crore), which includes alleged overcharge amount, penalty, and interest. The NPPA alleges that Natco overcharged for 2 drugs during the period April-2023 to November-2023, in violation of the Drugs Price Control Order, 2013 (DPCO). The company states there is no material impact on its financial, operational, or other activities. The disclosure was delayed due to technical and procedural issues in information flow, and the company has since complied with SEBI LODR requirements.
While the demand amount of ~₹4.92 crore is material in absolute terms, the company has indicated no material financial impact. However, this represents a regulatory risk related to drug pricing compliance and could attract investor attention given the penalty component.